Active Ingredient: Acamprosate Calcium

Dosage Form; Route: Delayed release tablet; oral

Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, partial or fully replicated crossover design in-vivo
   Strength: 333 mg
   Subjects: Normal healthy males and females, general population. Females should not be pregnant, and if applicable, should practice abstention or contraception during the study

   Additional comments: Applicants may consider using a reference-scaled average bioequivalence approach for Acamprosate Calcium. If using this approach, please provide evidence of high variability (i.e., within-subject variability $\geq 30\%$) in the bioequivalence parameters such as AUC and/or $C_{\text{max}}$ for the reference product. For general information on this approach, please refer to Guidance for industry Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. For details about the method of statistical analysis using the reference-scaled average bioequivalence approach for Acamprosate Calcium tablets, refer to the product specific guidance for Progesterone capsule.

2. Type of study: Fed
   Design: Single-dose, partial or fully replicated crossover design in-vivo
   Strength: 333 mg
   Subjects: Normal healthy males and females, general population. Females should not be pregnant, and if applicable, should practice abstention or contraception during the study

   Additional comments: Same as additional comments above

Analytes to measure: Acamprosate in plasma*
*Acamprosate exists completely dissociated in plasma. Therefore, bioequivalence measures may be reported in terms of acetylhomotaurine.

Bioequivalence based on (90% CI): Acamprosate*
*Please refer to the above section
Waiver request of in-vivo testing: Not Applicable

Dissolution test method and sampling times:

The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the ANDA.